NCT01497834 - A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

June 30, 2013

Conditions

Hepatitis C

Interventions

DRUG

BMS-790052 (Daclatasvir)

Tablets, Oral, 60mg, Once daily, 24 weeks

DRUG

BMS-650032 (Asunaprevir)

Capsules, Oral, 100mg, Twice daily, 24 weeks

Trial Locations (24)

1058470

Local Institution, Minato-ku

1138655

Local Institution, Bunkyo-Ku

1428666

Local Institution, Shinagawa-ku

1808610

Local Institution, Musashino-shi

2138587

Local Institution, Kawasaki-Shi

2608677

Local Institution, Chiba

4093898

Local Institution, Chuo-shi

4668560

Local Institution, Nagoya

5038502

Local Institution, Ogaki-shi

5458586

Local Institution, Osaka

5640013

Local Institution, Suita

5650871

Local Institution, Suita-shi

5898511

Local Institution, Osaka-sayama-shi

6608511

Local Institution, Amagasaki-shi

7008558

Local Institution, Okayama

7340037

Local Institution, Hiroshima

7608557

Local Institution, Takamatsu

8108563

Local Institution, Fukuoka

8300011

Local Institution, Kurume

8908520

Local Institution, Kagoshima

9208641

Local Institution, Kanazawa

9808574

Local Institution, Sendai

0600033

Local Institution, Sapporo

350-0495

Local Institution, Iruma-Gun